Bullish
IMUNON Secures Up to $10 Million Financing to Advance Phase 3 Ovarian Cancer Trial
IMUNON (Nasdaq: IMNN) has secured up to $10 million in financing to bolster its Phase 3 OVATION 3 study of IMNN-001 for advanced ovarian cancer. This ...